Online inquiry

IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7558MR)

This product GTTS-WQ7558MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets GPC3 gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001164617.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2719
UniProt ID P51654
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ7558MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3271MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ART621
GTTS-WQ4647MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ15517MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7858
GTTS-WQ14153MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ176MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ292MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ1147MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ8371MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aTROP2S7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW